|
|
|
31.05.26 - 15:03
|
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine....
|
|
|
30.05.26 - 14:03
|
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, May 30, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors....
|
|
|
|
|
|
|
|
|
21.04.26 - 16:30
|
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA....
|
|
|
17.04.26 - 21:03
|
PRAME-directed Cell Therapy Using Immatics′ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, April 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics' PRAME T-cell receptor (TCR) has been accepted for a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA. The patient case will be presented on April 21, 2026, at 2:00 pm PDT (Late-Breaking Research: Clinical Research 3; Poster Section 52; Poster Board Number 7; Abstract Number LB326) by the treating physician, Dr. med. Christian M. Seitz, Group Leader at the Hopp Children's Cancer Center Heidelberg (KiTZ)....
|
|
|
|
|
22.12.25 - 11:36
|
Immatics steht 2026 vor dem ersten Durchbruch (GoingPublic)
|
|
|
Bildnachweis: Art_spiral – stock.adobe.com, Immatics N.V.. Dank der jüngsten Fortschritte in der klinischen Pipeline hat die Aktie der auf Krebstherapien spezialisierten Biotechfirma ihren Börsenwert in den letzten drei Monaten in […]
Der Beitrag Immatics steht 2026 vor dem ersten Durchbruch erschien zuerst auf GoingPublic.de....
|
|
|
11.12.25 - 13:03
|
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enhanced pharmacology of IMA203CD8 reported previously, IMA203CD8 provides the potential to address difficult-to-treat solid tumors expressing PRAME beyond melanoma, such as ovarian cancer....
|
|
|
|
|
05.12.25 - 12:03
|
Immatics Announces $125 Million Underwritten Offering (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions. ...
|
|
|
|
|
|
|
|
|
27.10.25 - 12:03
|
Immatics Appoints Amie Krause as Chief People Officer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics' human resources, focusing on organizational development and operations as the company transitions to commercial stage.“As we enter our next phase of transforming into a commercial-stage enterprise, we are delighted to welcome Amie. Her experience in building high-performing teams as well as enhancing organizational excellence and efficiency will help position us for continued success as we strengthen our global leadership i...
|
|
|
|
|
|
|
01.10.25 - 13:03
|
Immatics Appoints Venkat Ramanan as Chief Financial Officer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics' current CFO, Arnd Christ.“We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PR...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
